TheEdgeResearch
Home / Stocks / ABT

Abbott Laboratories (ABT)

NYSE Healthcare Medical - Devices
$102.72 ▲ +0.11%
Market Cap
$177.75B
Sector
Healthcare
Industry
Medical - Devices
Beta
0.59
52-Wk Range
81.97-137.49
CEO
Robert Ford
Country
US
Currency
USD

Abbott Laboratories operates in the Medical - Devices industry of the Healthcare sector, headquartered in Abbott Park, IL, US. The stock last traded at $102.72, up 0.11% on the session, giving a market capitalisation of $177.75B. On trailing twelve-month figures it carries a trailing P/E of 33.03, a net margin of 11.6%. Its beta of 0.59 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
33.03
Price / Sales
3.82
Price / Book
3.50
EV / EBITDA
20.64
Gross margin
56.8%
Operating margin
17.0%
Net margin
11.6%
Return on equity
Debt / equity
0.64
Current ratio
1.38
Dividend yield
2.4%
Payout ratio
78.5%
Company profile
Exchange
New York Stock Exchange
Employees
115,000
IPO date
1980-03-17
Headquarters
Abbott Park, IL, US
About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Comparable companies

Abbott Laboratories is most often compared with the following Healthcare names:

BSXGILDISRGMDTMRKNVONVSSYKTMOUNH
More research on ABT
ABT technical analysis ABT TheEdge Score Compare against peers
Open full interactive analysis & DCF →